
    
      To evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in
      adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of
      Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change from
      Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.
    
  